BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical
company founded to discover, create, test, and deliver transformative
medicines to treat patients who suffer from genetic diseases. BridgeBio’s
pipeline of development programs ranges from early science to advanced
clinical trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers and innovators are committed to applying
advances in genetic medicine to help patients as quickly as possible. For
more information visit
bridgebio.com
and follow us on
LinkedIn,
Twitter
and
Facebook.